Syros Pharmaceuticals Inc   (SYRS)
Other Ticker:  

Syros Pharmaceuticals Inc

Business Description

Syros Pharmaceuticals Inc is a biotechnology company that focuses on developing gene control medicines. The company was founded in 2013 and is based in Cambridge, Massachusetts. Syros aims to pioneer a new way of treating diseases by targeting the gene control circuits that govern the expression of genes.

Syros Pharmaceuticals is known for its expertise in gene control through its proprietary platform known as Gene Control Science. This platform allows Syros to identify the genes and regulatory elements that control the expression of genes, thereby guiding the development of new medicines. The company believes that by understanding the gene control circuits, it can develop targeted therapies for various diseases.

One of the key areas of focus for Syros is cancer. The company believes that many cancers arise due to dysregulation of gene control circuits. By investigating and understanding the gene control circuits specific to cancer cells, Syros aims to develop precision therapies that can selectively modulate these circuits and halt cancer progression.

Syros has developed a portfolio of proprietary drug candidates, including SY-1425, SY-5609, and SY-2101. SY-1425 is being developed as a potential treatment for acute myeloid leukemia (AML) and relapsed/refractory Myelodysplastic Syndrome (MDS). SY-5609 is being developed as a potential treatment for breast, colorectal, ovarian, and lung cancers. SY-2101 is being developed as a potential treatment for sickle cell disease.

The company has also entered into various partnerships and collaborations to leverage its gene control expertise. Syros has collaborations with large pharmaceutical companies such as Global Blood Therapeutics, Inc., Orion Corporation, and Incyte Corporation to develop innovative therapies for various diseases.

Syros Pharmaceuticals has a multidisciplinary team of scientists, researchers, and industry experts who work collaboratively towards achieving the company*s mission. The company*s team includes experts in genomics, biology, chemistry, and clinical development. Syros emphasizes a data-driven approach and leverages cutting-edge technologies to drive its research and development efforts.

As of now, Syros is in the clinical stage of drug development, with its lead drug candidates being evaluated in clinical trials. The company is committed to advancing its pipeline of gene control medicines and bringing innovative treatments to patients in need.

Overall, Syros Pharmaceuticals Inc is a biotechnology company that is pioneering the development of gene control medicines. With its proprietary Gene Control Science platform, the company aims to target gene control circuits to develop precision therapies for various diseases, particularly cancer. Through its research, partnerships, and dedicated team, Syros is advancing the field of gene control and striving to make a significant impact in the healthcare industry.

View Company Supplier View Company Competition View Company Customers


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com